SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
NCT07129187
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Early Breast Cancer
HER2 + Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Interventions
DRUG:
SHR-A1811
Sponsor
Chuan Wang